UK ATTR Amyloidosis Launch Readiness

ATTR's binding constraint is the tafamidis comparator: any new CM stabiliser is judged against its NICE TA984 QALY model, while most of the addressable UK population still sits undiagnosed.

Tafamidis (Vyndaqel 61mg, Pfizer) is NHS England's commissioned ATTR-CM standard via NICE's standard Technology Appraisal route: recommended under TA984 (June 2024), which replaced the 2021 TA696 rejection, with a confidential simple-discount patient access scheme. Uptake has grown fast since 2023 commissioning (3,000-4,000 patients today, adding 1,500-2,000/year), but that growth is diagnosis-limited, not treatment-limited: true UK ATTRwt-CM prevalence is estimated at 20,000-40,000, meaning 15,000-36,000 patients remain undiagnosed. Acoramidis (Beyonttra in the UK, Bayer; marketed as Attruby in the US under the BridgeBio/Bayer partnership), MHRA-approved in late April 2025, received a positive NICE recommendation under TA1121 (published 14 January 2026), setting the second CM-stabiliser comparator bar. On the polyneuropathy side, NICE has recommended vutrisiran (Alnylam) for hereditary ATTR polyneuropathy since TA868 (15 February 2023), with a simple discount patient access scheme, and for ATTR-CM since TA1115 (December 2025).

No single NICE-commissioned UK drug currently covers both cardiomyopathy and polyneuropathy, even though some ATTR patients present with mixed phenotype and today receive vutrisiran for PN with no formal CM treatment, a genuine dual-indication white space. But the harder near-term reality for any new CM stabiliser is the NICE comparator: cost-effectiveness is assessed relative to tafamidis's TA984 QALY model and now also to acoramidis's TA1121 recommendation, and a new entrant must show either superiority in QALY terms or equivalence at a lower effective NHS price against both. The National Amyloidosis Centre (NAC, UCL/Royal Free, led by Professor Hawkins) is NICE's appointed clinical expert for every ATTR appraisal to date, and its published family-cascade and pre-symptomatic ATTRv surveillance registry (400-500 patients under monitoring) is the deepest UK evidence base available to any pre-launch sponsor.

The pre-launch sequence: formal scientific collaboration with NAC (research grant, registry data access, clinical advisory relationship) is the single highest-return UK investment, typically £100,000-300,000 over 2-3 years, because NAC's clinical-expert testimony materially shapes NICE committee outcomes. In parallel, invest in the Tc-PYP nuclear-cardiology referral pathway from NHS echo labs (available at only ~50 of the relevant NHS cardiac centres) to grow the diagnosed population ahead of submission. If clinical evidence is uncertain relative to tafamidis or acoramidis, settle the evidence plan with that uncertainty in view well before submission. Acoramidis's positive TA1121 recommendation (14 January 2026) has now reset the CM-stabiliser comparator bar; any new submission must be benchmarked against both tafamidis and acoramidis.